Registro de fonte primária
Nível de decisãoResultados topline
Nurix reports updated Phase 1/1b data for bexobrutideg (NX-5948) in CLL/SLL at EHA 2026
Nurix presented updated Phase 1a/1b results for bexobrutideg showing median PFS of 22.1 months and ORR of 83% in heavily pretreated r/r CLL/SLL patients, plus 92.9% ORR in BTKi-pretreated/BCL2-naive patients. The asset was well tolerated with low discontinuation rate due to AEs. This supports ongoing registrational Phase 2/3 trials and Roche collaboration.
Fatos principais
- Arquivado
- 13 de out. de 2026, 10:19
- Evento
- Resultados topline
- Direção
- Positivo
- Empresa
NRIXNurix Therapeutics- Ativo
- bexobrutideg
- Fonte
- SEC 8-K
- Confiança
- Com fonte
- taxa de resposta global
- 83,0%
- sobrevida livre de progressão mediana
- 22,1 meses
- taxa de resposta global btnk ingênuos
- 84,2%
- taxa de resposta global em linha anterior
- 92,9%
- descontinuação por evento adverso
- 5,6%
Trecho da fonte
EX-99.1 2 nrix-20261013xexx991.htm EX-99.1 Document Exhibit 99.1 [Nurix logo] Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL Advanced bexobrutideg combination strategy with initiation of recruiting for the Phase 1b/2 NX-5948-203 study Earned $27M from Gilead, Pfizer and Sanofi collaborations, including a $10M milestone from Sanofi for first patient dosed in the STAT6 degrader Phase 1 trial Advanced NX-1607 into Phase 1b expansion cohorts in MSS CRC, NSCLC, CRPC and melanoma with the first patient dosed in September 2026 Following receipt of the $700 million upfront as part of the close of the Roche col